Drugs / JTT-302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00748852 | Jan 2007 → Mar 2008 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00749788 | Dec 2006 → Feb 2008 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTT-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00749788 ↗ |
| Route | Oral | “JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal” NCT00748852 ↗ |